au en false false Default
HLTHAU VanEck Global Healthcare Leaders ETF Please read important disclosure Close important disclosure false

    • HLTH
    VanEck Global Healthcare Leaders ETF

    HLTH
    VanEck Global Healthcare Leaders ETF

    • NAV
      $11.84

      as at 16-Feb-26
    • Total Net Assets
      $52.18M
    • Dividend Frequency
      1 each year
    • Management fee (p.a.)
      0.45%
    • Number of securities
      50
    • Inception Date
      08-Sep-20
    The NAV is generally calculated daily after all markets are closed for that day based on the closing price of the securities on the relevant foreign stock exchange. The NAV is then converted to AUD based on the relevant London WM Reuters 4pm exchange rate. This means, due to Australia’s time zone, that the NAV will generally not be updated until around 3pm next business day.
    HLTH-VanEck-Global-Healthcare-ETF-Tile.webp

    Overview

    Fund Description

    Our global healthcare ETF, HLTH gives investors exposure to a diversified portfolio of the largest international companies from the global healthcare sector. Our global healthcare ETF aims to provide investment returns, before fees and other costs, which track the performance of the Index. 

    Key benefits

    Global growth opportunity

    A sector with significant growth potential due to shifting global demographics, social changes, research & development and innovation supporting increased demand in healthcare-related products and services.

    A portfolio of global healthcare leaders comprising the most fundamentally strong companies

    Invests in 50 fundamentally sound and attractively valued companies with the best growth prospects in the healthcare sector.

    Targeted exposure and diversification

    A portfolio which targets focused exposure to healthcare and offers true diversification by equally weighting across companies.
      is likely to be appropriate for a consumer who is seeking capital preservation and a regular income distribution, is intending to use the product as a minor or satellite allocation within a portfolio, has an investment timeframe of at least 3 years, and has a medium risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth, is intending to use the product as a minor or satellite allocation within a portfolio, has an investment timeframe of at least 7 years, and has a very high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth, is intending to use the product as a minor or satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a very high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth, is intending to use the product as a minor or satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a high to very high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth and a regular income distribution, is intending to use the product as a minor or satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth and a regular income distribution, is intending to use the product as a minor or satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a very high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth, is intending to use the product as a core, minor or satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth, is intending to use the product as a major, core, minor or satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital preservation and a regular income distribution, is intending to use the product as a core, minor or satellite allocation within a portfolio, has an investment timeframe of at least 3 years, and has a medium risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth and a regular income distribution, is intending to use the product as a core, minor or satellite allocation within a portfolio, has an investment timeframe of at least 7 years, and has an extremely high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth and a regular income distribution, is intending to use the product as a core, minor or satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a high risk/return profile.
      is likely to be appropriate for a consumer who is seeking a regular income distribution, is intending to use the product as a minor or satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a very high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth, is intending to use the product as a minor or satellite allocation within a portfolio, has no investment timeframe, and has a high or very high risk/return profile.
      is likely to be appropriate for a consumer who is seeking regular income distribution, is intending to use the product as a core, minor or satellite allocation within a portfolio, has an investment timeframe of at least 3 years, and has a medium risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth, is intending to use the product as a satellite allocation within a portfolio, has no minimum investment timeframe, and has an extremely high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth and a regular income distribution, is intending to use the product as a minor or satellite allocation within a portfolio, has an investment timeframe of at least 3 years, and has a high risk/return profile.
      is likely to be appropriate for a consumer who is seeking a regular income distribution, is intending to use the product as a minor or satellite allocation within a portfolio, has an investment timeframe of at least 3 years, and has a medium risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital preservation and a regular income distribution, is intending to use the product as a standalone solution or major, core, minor or satellite allocation within a portfolio, has no minimum investment timeframe, and has a low risk/return profile.

    Index Key points

    Underlying Index

    MarketGrader Developed Markets (ex-Australia) Health Care Index

    Overview

    The Index consists of 50 fundamentally sound companies with the best growth at a reasonable price (GARP) attributes in the healthcare sector from developed markets excluding Australia.

    Summary of Index methodology

    The Index seeks to identify the largest companies in the health care sector with the best growth at a reasonable price (GARP) attributes, being the best drivers of long-term capital appreciation. The Index constituents are selected on the basis of the strength of their fundamentals across four factor categories: growth, value, profitability and cash flow. The 50 Index constituents are equally weighted at each semi-annual rebalance.

    For full details of the methodology, click here.

    Rebalances

    The Index is reviewed and rebalanced on a semi-annual basis, usually as of the close of the third Friday of March and September.

    Index provider

    MarketGrader.com Corporation ('MarketGrader'). MarketGrader is not a related body corporate of VanEck.

    "MarketGrader" and "MarketGrader Developed Markets (Ex-Australia) Health Care Index" are trademarks of MarketGrader.com Corp. and have been licensed for use for certain purposes by VanEck. HLTH is based on the MarketGrader Developed Markets Health Care Net Return AUD Index, but is not sponsored, endorsed, sold or promoted by MarketGrader, and MarketGrader makes no representation regarding the advisability of investing in HLTH.

    Performance

    Holdings & allocations

    All holdings (%) as at 17-Feb-26 Download all holdings

    No. of holdings: 50
    Holding name
    Ticker
    No. of securities held
    		 Market value % of Fund net
    assets
    Swedish Orphan Biovitrum Ab SOBI SS 23,208 1,488,854 2.85
    Globus Medical Inc GMED US 11,425 1,423,620 2.73
    Merck & Co Inc MRK US 8,104 1,391,763 2.67
    Regeneron Pharmaceuticals Inc REGN US 1,198 1,361,055 2.61
    Eli Lilly & Co LLY US 888 1,306,344 2.50
    Ucb Sa UCB BB 2,759 1,298,639 2.49
    Johnson & Johnson JNJ US 3,769 1,297,918 2.49
    Biogen Inc BIIB US 4,633 1,287,895 2.47
    Amgen Inc AMGN US 2,428 1,267,973 2.43
    Chugai Pharmaceutical Co Ltd 4519 JP 14,810 1,267,146 2.43
    Bristol-Myers Squibb Co BMY US 14,526 1,248,050 2.39
    Astrazeneca Plc AZN SS 4,191 1,217,439 2.33
    Ensign Group Inc/The ENSG US 3,995 1,205,592 2.31
    Shionogi & Co Ltd 4507 JP 37,300 1,186,201 2.27
    Penumbra Inc PEN US 2,461 1,181,155 2.26
    Hoya Corp 7741 JP 4,639 1,172,952 2.25
    Illumina Inc ILMN US 7,055 1,165,704 2.23
    Universal Health Services Inc UHS US 3,500 1,162,508 2.23
    Otsuka Holdings Co Ltd 4578 JP 11,700 1,155,063 2.21
    Incyte Corp INCY US 8,076 1,154,938 2.21
    Tenet Healthcare Corp THC US 3,480 1,137,602 2.18
    United Therapeutics Corp UTHR US 1,657 1,110,198 2.13
    Pfizer Inc PFE US 28,115 1,096,841 2.10
    Quest Diagnostics Inc DGX US 3,669 1,073,635 2.06
    Exelixis Inc EXEL US 17,142 1,064,964 2.04
    Biomarin Pharmaceutical Inc BMRN US 12,407 1,050,721 2.01
    Argenx Se ARGX US 887 1,031,301 1.98
    Intuitive Surgical Inc ISRG US 1,492 1,025,353 1.97
    Alk-Abello A/S ALKB DC 20,716 999,757 1.92
    Genmab A/S GMAB DC 2,373 996,602 1.91
    Halozyme Therapeutics Inc HALO US 8,727 980,653 1.88
    Samsung Biologics Co Ltd 207940 KS 584 977,614 1.87
    Orion Oyj ORNBV FH 8,397 959,587 1.84
    West Pharmaceutical Services Inc WST US 2,647 937,898 1.80
    Idexx Laboratories Inc IDXX US 1,047 932,074 1.79
    H Lundbeck A/S HLUNB DC 99,803 900,575 1.73
    Sk Biopharmaceuticals Co Ltd 326030 KS 8,394 897,326 1.72
    Resmed Inc RMD US 2,484 887,381 1.70
    Novo Nordisk A/S NOVOB DC 12,264 846,914 1.62
    Neurocrine Biosciences Inc NBIX US 4,730 830,451 1.59
    Encompass Health Corp EHC US 5,324 829,458 1.59
    Zoetis Inc ZTS US 4,528 811,191 1.55
    Abbott Laboratories ABT US 5,018 799,814 1.53
    Daiichi Sankyo Co Ltd 4568 JP 28,000 762,686 1.46
    Ypsomed Holding Ag YPSN SW 1,304 715,664 1.37
    Alteogen Inc 196170 KS 1,896 709,023 1.36
    Boston Scientific Corp BSX US 6,534 690,693 1.32
    Insulet Corp PODD US 1,964 674,364 1.29
    Terumo Corp 4543 JP 38,300 673,961 1.29
    Corcept Therapeutics Inc CORT US 9,209 520,664 1.00
    Other/Cash --   12,552 0.02
    Total 100.00
    These are not recommendations to buy or to sell any security.

    Dividends

    Election of Dividend Reinvestment Plan (DRP)

    You can elect DRP by logging into MUFG’s Investor Centre. Once you are logged in, please proceed to the “Payments and Tax” tab and select “Reinvestment Update”.

    Documents & insights

    HLTHAU https://google.com/
    Exchange Traded Funds (ETFs)
    Information about
    Education
    Connect with us